Royalty pharma plc RPRX 深 滬
等待開盤 03-26 09:30:00 美东时间
47.03
+1.460
+3.20%
華盛通- 最 高47.08
- 今 開45.80
- 成交量 326.81万股
- 最 低 45.79
- 昨 收 45.57
- 總市值 271.30亿
- 52周最高 47.86
- 市盈率 靜 26.40
- 換手率 0.57%
- 52周最低 28.765
- 委 比 -64.66%
- 總股本 5.77亿
- 歷史最高 52.005
- 量 比 0.79
- 振 幅 2.83%
- 歷史最低 22.935
- 每 手 1
- 風險率 4.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
Royalty Pharma appoints Lucas Glass as Head of Artificial Intelligence, effective April 2026. With over a decade of experience in AI and data solutions, Glass will lead the implementation of cutting-edge AI capabilities, enhancing the company's decision-making and operational efficiency. His appointment underscores Royalty Pharma's commitment to leveraging advanced technologies to strengthen its competitive edge in the biopharmaceutical sector.
03-23 11:15
Royalty Pharma Announces Expansion of Leadership Team
Royalty Pharma appoints Greg Butz as Executive Vice President, Partnering & Investments, effective June 2026. Butz joins from Bank of America, where he was Global Co-Head of Healthcare Investment Banking. The company also promotes Chris Hite to Chairman, Partnering & Investments. Royalty Pharma specializes in acquiring and funding biopharmaceutical royalties, with a portfolio of over 35 commercial products and 19 development-stage candidates.
03-17 20:01
Shares of pharmaceutical companies are trading lower amid overall market weakness due to the ongoing conflict in the Middle East.
Shares of pharmaceutical companies are trading lower amid overall market weakne...
03-06 03:56
Vera Therapeutics Appoints Christopher Hite to Board of Directors
Vera Therapeutics announced the appointment of Christopher Hite to its Board of Directors. Hite, with over 25 years of experience in biopharmaceutical finance and strategy, will contribute to Vera's growth, particularly as it prepares to launch its first-in-class dual BAFF/APRIL inhibitor for IgA nephropathy, atacicept. Vera Therapeutics specializes in developing treatments for serious immunological diseases.
03-05 14:00
Royalty Pharma Provides Zymeworks $250 Million Royalty-Backed Note Financing
Royalty Pharma Provides Zymeworks $250 Million Royalty-Backed Note Financing Royalty Pharma has agreed to provide Zymeworks with $250 million through a non-recourse, royalty-backed note financing tied to Ziihera. The note will be repaid using 30% of Zymeworks’ worldwide tiered royalties on Ziihera u
03-02 19:15
Canada's Zymeworks 2025 revenue rises 39%
Canada's Zymeworks 2025 revenue rises 39% Overview Biotechnology firm's 2025 revenue rose 39% yr/yr, driven by clinical milestones Net loss for 2025 reduced by 34% compared to previous year Company utilized $62.5 mln for share repurchases under current program Outlook Zymeworks expects adjusted oper
03-02 19:08
Zymeworks Secures $250 Million Royalty-Backed Note Financing From Royalty Pharma
Zymeworks Secures $250 Million Royalty-Backed Note Financing From Royalty Pharma Zymeworks Inc. has entered a $250 million non-recourse royalty-backed note financing with Royalty Pharma. Repayment will come from 30% of Zymeworks’ worldwide tiered royalties on Ziihera owed by partners Jazz Pharmaceut
03-02 19:01
Zymeworks FY 2025 revenue rises 39% to USD 106.0 million
Zymeworks FY 2025 revenue rises 39% to USD 106.0 million Zymeworks (ZYME) reported FY 2025 total revenue of USD 106.0 million, up 39%, and a FY net loss of USD 81.1 million, down 34%. In Q4 2025, revenue was USD 2.5 million and net loss was USD 41.2 million. FY 2025 R&D expenses were USD 137.0 milli
03-02 19:01
